Condition
KRAS G12C Mutation clinical trials and research
As of November 12, 2026, Find a Trial lists 2 KRAS G12C Mutation clinical trials that are recruiting, at sites in 2 countries (most in China (1), United States (1)). By phase: Phase 2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Neoadjuvant fulzerasib followed by sintilimab plus platinum-doublet chemotherapy for resectable KRAS G12C-mutant NSCLC
This will test whether giving fulzerasib first, then sintilimab with platinum-doublet chemotherapy before surgery helps people with resectable KRAS G12C‑mutant stage IB–IIIA non‑small cell lung cancer.
-
Investigating KQB365 for treating advanced solid tumors
This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.
Related topics
Quick answers
How many KRAS G12C Mutation clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.